533 related articles for article (PubMed ID: 15090831)
1. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
3. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
4. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Santin M; Shaw E; Garcia MJ; Delejido A; de Castro ER; Rota R; Altés J; Baguena F; Valero S; Sala M; Casanova A;
AIDS Res Hum Retroviruses; 2006 Apr; 22(4):315-20. PubMed ID: 16623633
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
Gonvers JJ; Heim MH; Cavassini M; Müllhaupt B; Genné D; Bernasconi E; Borovicka J; Cerny A; Chave JP; Chuard C; Dufour F; Dutoit V; Malinverni R; Monnat M; Negro F; Troilliet N; Oneta C
Swiss Med Wkly; 2010; 140():w13055. PubMed ID: 20648398
[TBL] [Abstract][Full Text] [Related]
7. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
8. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
10. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
13. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
14. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
Ballesteros AL; Franco S; Fuster D; Planas R; Martínez MA; Acosta L; Sirera G; Salas A; Tor J; Rey-Joly C; Clotet B; Tural C
AIDS; 2004 Jan; 18(1):59-66. PubMed ID: 15090830
[TBL] [Abstract][Full Text] [Related]
15. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
[TBL] [Abstract][Full Text] [Related]
16. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
Payan C; Pivert A; Morand P; Fafi-Kremer S; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F;
Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
[TBL] [Abstract][Full Text] [Related]
17. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
18. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
[TBL] [Abstract][Full Text] [Related]
19. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
